Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen, Novartis Team on RT-qPCR Tools

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asuragen today said that it has entered into an exclusive collaboration with Novartis to develop tools intended to aid laboratories with standardization of BCR-ABL1 RT-qPCR testing to the international scale.

The Austin, Texas-based firm said that it would distribute the Armored RNA Quant BCR-ABL1 RNA International Scale calibrators and software reporting tools directly or through distributors worldwide.

"Our development of the BCR-ABL1 RNA IS Calibrators and software tool leverages both our expertise in molecular diagnostic assay development and our proprietary Armored RNA technology," Asuragen President Rollie Carlson noted in a statement.

Asuragen said that the calibrators are intended to be compatible with "several widely used assays, including both commercially available and laboratory developed tests."

Financial and other terms of the alliance were not disclosed.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

Higher polygenic risk scores for attention-deficit/hyperactivity disorder were also linked to cognitive decline and Alzheimer's disease risk, according to a new study in Molecular Psychiatry.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.